🇺🇸 FDA
Pipeline program

Pembrolizumab

KEYNOTE-715-06/ECHO-306-06

Phase 2 small_molecule completed

Quick answer

Pembrolizumab for Lung Cancer is a Phase 2 program (small_molecule) at Incyte with 2 ClinicalTrials.gov record(s).

Program details

Company
Incyte
Indication
Lung Cancer
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials